MGI Tech filed plans to acquire STOmics and CycloneSeq—two BGI Group subsidiaries commercializing spatial (Stereo‑Seq) and nanopore sequencing technologies—for RMB 365.7 million (~$52.6 million). MGI said it will invest additional capital to expand commercial operations and integrate the technologies into its broader product portfolio. The deal brings BGI’s long‑read and spatial assets closer to MGI’s ‘Seq All’ strategy to offer a one‑stop shop for sequencing customers. STOmics offers spatial transcriptomics compatible with fresh‑frozen and FFPE samples; CycloneSeq commercializes BGI’s nanopore platforms. MGI expects both subsidiaries to reach profitability within a specified timeframe and will seek shareholder approval in March. Consolidation in sequencing markets reflects competition among vendors to cover complementary modalities—short‑read, long‑read, spatial—and to capture growing demand from clinical and research customers for integrated multiomic workflows.